Zoledronic acid shows long-term benefit in survivorship for premenopausal ER-positive breast cancer
Wednesday, December 7, 2011 - 11:00
in Health & Medicine
Researchers have proven the continuing effectiveness of treating patients with estrogen receptor-positive premenopausal breast cancer with adjuvant zoledronic acid in addition to adjuvant endocrine treatment including ovarian function suppression.